Drug profile

The FDA adverse-event record for Triamcinolone Acetonide (Injectable)

19 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Triamcinolone Acetonide (Injectable). See the species affected, top reactions, and outcomes below.

19
adverse-event reports
21.1%
death-coded share
Dog
most-reported species
9
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
19
Total Reports
4
Deaths Reported
21.1%
Death Rate

Active Ingredients

Triamcinolone Acetonide (Injectable)

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 15
Cat 4

Most Affected Breeds

Terrier - Bull - American Pit 2
Domestic Shorthair 2
Terrier - Yorkshire 1
Boxer (German Boxer) 1
Bulldog - American 1
Chihuahua 1
Collie - Border 1
Shepherd Dog - Australian 1
Shepherd (unspecified) 1
Terrier (unspecified) 1

Most Reported Reactions

Vomiting 9
Lethargy (see also Central nervous system depression in 'Neurological') 5
Death 3
Hives (see also 'Skin') 3
Anaphylaxis 3
Cyanosis 2
Tachycardia 2
Decreased appetite 2
Lack of efficacy - NOS 2
Facial swelling (see also 'Skin') 2
Nystagmus 2
Head tilt - neurological disorder (see also Head tilt - ear disorder) 2

Outcome Breakdown

Ongoing
11 (57.9%)
Died
3 (15.8%)
Recovered/Normal
2 (10.5%)
Outcome Unknown
2 (10.5%)
Euthanized
1 (5.3%)

Triamcinolone Acetonide (Injectable) Adverse Event Insights

19 reports name Triamcinolone Acetonide (Injectable); 4 recorded a death outcome (21.1% of reported events, not a population-level mortality rate). Active ingredient: Triamcinolone Acetonide (Injectable). Administration routes: Unknown, Subcutaneous.

By species: Dog (15 reports), Cat (4 reports). By breed: Terrier - Bull - American Pit (2), Domestic Shorthair (2), Terrier - Yorkshire (1).

Leading clinical signs: Vomiting (9), Lethargy (see also Central nervous system depression in 'Neurological') (5), Death (3), Hives (see also 'Skin') (3). Outcome, 19 coded reports: Ongoing leads at 57.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.